Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...
Q4 2025 Earnings Call March 17, 2026 8:30 PM EDTCompany ParticipantsSophie Li - Investor Relations DirectorMeisong Lai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results